PubRank

M Gerlach

Author PubWeight™ 95.35‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990 3.93
2 Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992 3.64
3 AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 2011 2.91
4 Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995 2.19
5 The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004 1.64
6 Brain iron pathways and their relevance to Parkinson's disease. J Neurochem 2001 1.55
7 Pre-hospital discharge testing after implantable cardioverter defibrillator implantation: a measure of safety or out of date? A retrospective analysis of 975 patients. Europace 2011 1.43
8 Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol 2005 1.37
9 Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 2001 1.33
10 High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm (Vienna) 2004 1.26
11 Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res 2006 1.26
12 Early detection of increased tumour necrosis factor alpha (TNFalpha) and soluble TNF receptor protein plasma levels after trauma reveals associations with the clinical course. Acta Anaesthesiol Scand 2001 1.16
13 Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol 2001 1.09
14 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 1996 1.06
15 Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry 2001 1.05
16 The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm Suppl 2004 1.04
17 Microglia activation is related to substantia nigra echogenicity. J Neural Transm (Vienna) 2010 1.01
18 Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol 2001 1.00
19 Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport 1995 0.95
20 BCR-ABL and v-SRC tyrosine kinase oncoproteins support normal erythroid development in erythropoietin receptor-deficient progenitor cells. Proc Natl Acad Sci U S A 1999 0.93
21 Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J Neurochem 2000 0.92
22 Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest 1991 0.92
23 Impaired iron homeostasis in Parkinson's disease. J Neural Transm Suppl 2000 0.91
24 Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res 1989 0.91
25 Depression in Parkinson's disease: biogenic amines in CSF of "de novo" patients. J Neural Transm (Vienna) 1996 0.91
26 In vitro studies of ferritin iron release and neurotoxicity. J Neurochem 1998 0.90
27 Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol Teratol 2002 0.90
28 Advanced glycation end products in neurodegeneration: more than early markers of oxidative stress? Ann Neurol 1998 0.89
29 Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat. Behav Brain Res 2003 0.89
30 Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm (Vienna) 2001 0.89
31 Chronic alcohol consumption and cerebral indices of oxidative stress: is there a link? Alcohol Clin Exp Res 2001 0.88
32 Dopamine receptor agonists in the therapy of Parkinson's disease. J Neural Transm (Vienna) 2003 0.88
33 Interaction of attention and graphomotor functions in children with attention deficit hyperactivity disorder. J Neural Transm Suppl 2007 0.87
34 Subcellular proteomics reveals neuromelanin granules to be a lysosome-related organelle. J Neural Transm (Vienna) 2006 0.87
35 Anti-melanin antibodies are increased in sera in Parkinson's disease. Exp Neurol 2009 0.86
36 Behavioural and expressional phenotyping of nitric oxide synthase-I knockdown animals. J Neural Transm Suppl 2007 0.86
37 Regional and age-dependent expression of the nitric oxide receptor, soluble guanylyl cyclase, in the human brain. Brain Res 2001 0.85
38 Effects of secretin on extracellular amino acid concentrations in rat hippocampus. J Neural Transm (Vienna) 2004 0.85
39 Endothelium and regulation of coagulation. Diabetes Care 1991 0.85
40 Altered redox state of platelet coenzyme Q10 in Parkinson's disease. J Neural Transm (Vienna) 2000 0.85
41 Endothelial tissue factor stimulation by proteinase 3 and elastase. Clin Exp Immunol 2001 0.84
42 Allelic variants of SNAP25 in a family-based sample of ADHD. J Neural Transm (Vienna) 2008 0.84
43 Evidence for specific phases in the development of human neuromelanin. Neurobiol Aging 2006 0.84
44 MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat Disord 2000 0.83
45 Involvement of microglia in cerebrospinal fluid glutamate increase in SIV-infected rhesus monkeys (Macaca mulatta). AIDS Res Hum Retroviruses 1999 0.83
46 Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used. BMJ 1996 0.83
47 Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome. J Neural Transm (Vienna) 2005 0.82
48 Amino acid specificity of glycation and protein-AGE crosslinking reactivities determined with a dipeptide SPOT library. Nat Biotechnol 1999 0.82
49 Tyrosinase is not detected in human catecholaminergic neurons by immunohistochemistry and Western blot analysis. J Neural Transm Suppl 2007 0.81
50 5-HT2A promoter polymorphism -1438G/A in children and adolescents with obsessive-compulsive disorders. Mol Psychiatry 2002 0.81
51 Iron in the Parkinsonian substantia nigra. Mov Disord 1997 0.81
52 Coenzyme Q10 serum levels in Huntington's disease. J Neural Transm Suppl 2004 0.81
53 Chronic TVP-1012 (rasagiline) dose--activity response of monoamine oxidases A and B in the brain of the common marmoset. J Neural Transm Suppl 1998 0.81
54 Transmission disequilibrium studies in children and adolescents with obsessive-compulsive disorders pertaining to polymorphisms of genes of the serotonergic pathway. J Neural Transm (Vienna) 2004 0.81
55 Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. Pharmacopsychiatry 2009 0.81
56 Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells. J Neural Transm (Vienna) 2004 0.81
57 Parkinson's disease: a major hypokinetic basal ganglia disorder. J Neural Transm (Vienna) 1999 0.81
58 Pathogenesis and pathophysiology of attention-deficit/hyperactivity disorder: from childhood to adulthood. J Neural Transm (Vienna) 2008 0.81
59 Effects of the noradrenergic neurotoxin DSP4 on spatial memory in the rat. J Neural Transm (Vienna) 2007 0.81
60 Aspirin as a free radical scavenger: consequences for therapy of cerebrovascular ischemia. Stroke 1995 0.81
61 The effects of nitric oxide (NO) on platelet membrane receptor expression during activation with human alpha-thrombin. Blood Coagul Fibrinolysis 1996 0.80
62 Measurement of the mass energy-absorption coefficient of air for x-rays in the range from 3 to 60 keV. Phys Med Biol 2012 0.80
63 The neuromelanin of human substantia nigra: structure, synthesis and molecular behaviour. J Neural Transm Suppl 2003 0.80
64 The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. Exp Neurol 2003 0.79
65 [Neurobiology of attention-deficit hyperactivity disorder]. Nervenarzt 2008 0.79
66 Proteomics of the human brain: sub-proteomes might hold the key to handle brain complexity. J Neural Transm (Vienna) 2006 0.79
67 Characterization and regional distribution of nitric oxide synthase in the human brain during normal ageing. Brain Res 1999 0.79
68 Itches and scratches – is there a link between eczema, ADHD, sleep disruption and food hypersensitivity? Allergy 2011 0.79
69 Relevance of tumour necrosis factor-alpha and interleukin-1-alpha in the pathogenesis of hypoxia-related organ failure. Eur J Anaesthesiol 1993 0.79
70 Evidence for specific phases in the development of human neuromelanin. J Neural Transm (Vienna) 2006 0.79
71 Quantitation of 5HT3 receptors in forebrain of serotonin transporter deficient mice. J Neural Transm (Vienna) 2003 0.79
72 Measurement of the x-ray mass energy-absorption coefficient of air using 3 keV to 10 keV synchrotron radiation. Phys Med Biol 2006 0.79
73 Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood. J Neural Transm Suppl 2007 0.79
74 Therapeutic drug monitoring of children and adolescents treated with fluoxetine. Pharmacopsychiatry 2011 0.79
75 Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. Ther Drug Monit 2004 0.79
76 Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease? Neurosci Lett 1991 0.78
77 Evidence for increased oxidative stress in alcohol-dependent patients provided by quantification of in vivo salicylate hydroxylation products. Alcohol Clin Exp Res 1997 0.78
78 Relationship between ionized and total magnesium in serum. Scand J Clin Lab Invest Suppl 1996 0.78
79 No evidence for association between a functional promoter variant of the Norepinephrine Transporter gene SLC6A2 and ADHD in a family-based sample. Atten Defic Hyperact Disord 2011 0.78
80 Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes. J Neural Transm (Vienna) 2006 0.78
81 L-selectin in trauma patients: a marker for organ dysfunction and outcome? Eur J Clin Invest 1999 0.78
82 Brief review of available evidence concerning the potential induction of genomic damage by methylphenidate. J Neural Transm (Vienna) 2007 0.78
83 Therapeutic drug monitoring in child and adolescent psychiatry. Pharmacopsychiatry 2011 0.78
84 AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011 0.77
85 Nitric oxide diffusion across membrane lungs protects platelets during simulated extracorporeal circulation. Eur J Clin Invest 1999 0.77
86 Case report: intoxication with high dose of long-acting methylphenidate (Concerta(®)) in a suicidal 14-year-old girl. Atten Defic Hyperact Disord 2010 0.77
87 The serotonin transporter in Alzheimer's and Parkinson's disease. J Neural Transm Suppl 2000 0.77
88 Effects of Selegiline in a retroviral rat model for neurodegenerative disease. J Neurovirol 1999 0.76
89 Neural degeneration in Parkinson's disease. Adv Neurol 2001 0.76
90 Selegiline completely restores choline acetyltransferase activity deficits in simian immunodeficiency infection. Eur J Pharmacol 2001 0.76
91 Cerebral oligaemia episode triggers free radical formation and late cognitive deficiencies. Eur J Neurosci 2000 0.76
92 Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J Neural Transm (Vienna) 1996 0.76
93 A highly sensitive method for the determination of protein bound 3,4-dihydroxyphenylalanine as a marker for post-translational protein hydroxylation in human tissues ex vivo. Free Radic Res 2001 0.76
94 Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice. J Neural Transm Suppl 2007 0.76
95 Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats. J Neural Transm (Vienna) 2010 0.76
96 Treatment with antioxidants does not prevent loss of dopamine in the striatum of MPTP-treated common marmosets: preliminary observations. J Neural Transm Park Dis Dement Sect 1991 0.76
97 Increased hippocampal DNA oxidation in serotonin transporter deficient mice. J Neural Transm (Vienna) 2002 0.76
98 Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology 2002 0.75
99 A new hypothesis of neurodegenerative diseases: the deleterious network hypothesis. Med Hypotheses 1999 0.75
100 Structural investigations of neuromelanin by pyrolysis-gas chromatography/mass spectrometry. J Neural Transm (Vienna) 2006 0.75
101 [Contribution to the diagnosis and clinical picture of malignant reticulosis of the skin]. Arch Klin Exp Dermatol 1965 0.75
102 Exhaled nitric oxide in patients with Wegener's granulomatosis. Eur Respir J 1999 0.75
103 Tolcapone and neurotoxicity in Parkinson's disease. Lancet 1998 0.75
104 Pro- and antioxidative properties of cortical tissue preparations from human brain exhibiting NMDA-receptor characteristics. Z Naturforsch C 1999 0.75
105 Intraoperative microdialysis and tissue-pO2 measurement in human glioma. Acta Neurochir Suppl 1998 0.75
106 [ProSeal™laryngeal mask in normal weight and obese patients : oxygenation under pressure-controlled ventilation and different end-expiratory pressures]. Anaesthesist 2011 0.75
107 Antioxidative properties of aspirin: dose dependence and clinical implications. Eur J Neurol 1996 0.75
108 The interactions of 1-alkyl-4,4-diphenylpiperidines with opiate receptors. Eur J Pharmacol 1983 0.75
109 (-)-Deprenyl treatment of patients with Parkinson's disease does not affect erythrocyte catechol-O-methyl transferase activity. J Neural Transm Park Dis Dement Sect 1991 0.75
110 A sensitive procedure for the determination of protein bound 3,4-dihydroxyphenyl-alanine as a marker for posttranslational protein hydroxylation in human frontal cortex, liver, and red blood cells. Adv Exp Med Biol 2001 0.75
111 Development of AEZS-115 (ZEN-019) by optimization of structurally unique, orally active, peptidomimetic GnRH antagonists. Adv Exp Med Biol 2009 0.75
112 Detection and pharmacokinetics of tetrahydrogestrinone in horses. J Vet Pharmacol Ther 2009 0.75
113 [Removal of the laryngeal mask airway in the post-anesthesia care unit. A means of process optimization?]. Anaesthesist 2011 0.75
114 The effect of silyl substituted methotrexate in the treatment of experimental allergic encephalomyelitis in rats mediated by T-line cells. Neuropharmacology 1987 0.75
115 Genomic aspects of sporadic Parkinson's disease. Parkinsonism Relat Disord 2008 0.75
116 4,4-Diphenylpiperidine derivates and their sila analogues. A comparative study of their interaction with neural receptor biding sites and synaptosomal monoamine uptake. Arzneimittelforschung 1988 0.75
117 [Physical therapy for a child with poliomyelitis]. Kinderkrankenschwester 1993 0.75
118 Reduction of platelet trapping in membrane oxygenators by transmembraneous application of gaseous nitric oxide. Int J Artif Organs 1996 0.75
119 A novel technique for the isolation of Lewy bodies in brain. Acta Neuropathol 1998 0.75
120 Apoptosis inhibition in T cells triggers the expression of proinflammatory cytokines--implications for the CNS. J Neural Transm Suppl 2006 0.75
121 Role of iron in 6-hydroxydopamine neurotoxicity. Adv Neurol 1999 0.75
122 Consequences of a single short lasting cerebral oligemia and the influence of iron injected into the substantia nigra or in the ventrolateral striatum of the rat. Trigger of Parkinson's disease pathogenesis? J Neural Transm (Vienna) 2004 0.75
123 [Acetylsalicylic acid as free radical scavenger. An argument for increased dosages in acute and preventive therapy of vascular diseases]. Fortschr Med 1995 0.75
124 [Relation between Church and politics]. Dtsch Krankenpflegez 1973 0.75
125 The industrial chemical Tinuvin 123 does not induce dopaminergic neurotoxicity in C57Bl/6 mice. Neurosci Lett 2000 0.75
126 Is there neuroprotection in Parkinson syndrome? J Neurol 2000 0.75
127 Investigation of the lipid component of neuromelanin. J Neural Transm (Vienna) 2006 0.75
128 [Mercaptopurine and silylated mercaptopurine the treatment of experimental allergic encephalomyelitis]. Arzneimittelforschung 1990 0.75